Intellia Therapeutics (NASDAQ:NTLA) Downgraded to Strong Sell Rating by Wall Street Zen

Posted by Brian Himes on Aug 9th, 2026

Wall Street Zen cut shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday.

Several other research firms have also issued reports on NTLA. New Street Research set a $25.00 target price on Intellia Therapeutics in a report on Monday, June 15th. Morgan Stanley lifted their price target on Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a report on Monday, April 27th. Chardan Capital boosted their price objective on Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Wolfe Research downgraded Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective for the company. in a research note on Wednesday, July 15th. Finally, Sanford C. Bernstein raised their target price on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.85.

Check Out Our Latest Report on Intellia Therapeutics

Intellia Therapeutics Trading Up 6.2%

Shares of NASDAQ:NTLA opened at $11.94 on Friday. The stock’s fifty day simple moving average is $13.65 and its two-hundred day simple moving average is $13.48. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25. The stock has a market cap of $1.67 billion, a PE ratio of -3.55 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.80). The business had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 58.80%. The firm’s quarterly revenue was down 46.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.98) EPS. On average, sell-side analysts forecast that Intellia Therapeutics will post -3.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Michael P. Dube sold 2,641 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This represents a 3.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.50% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. raised its position in shares of Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after purchasing an additional 808 shares during the period. Comerica Bank boosted its holdings in Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Intellia Therapeutics by 36.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after buying an additional 948 shares during the period. Wealthfront Advisers LLC grew its stake in Intellia Therapeutics by 7.6% in the 1st quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock valued at $185,000 after buying an additional 1,018 shares in the last quarter. Finally, Benjamin Edwards Inc. grew its stake in Intellia Therapeutics by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after buying an additional 1,126 shares in the last quarter. Institutional investors own 88.77% of the company’s stock.

Key Headlines Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

Positive Sentiment: Evercore ISI upgraded Intellia Therapeutics, citing a favorable “nex-z hypothesis.” The upgrade suggests the firm sees greater potential in Intellia’s gene-editing pipeline, providing the clearest positive catalyst in the recent news flow. Intellia upgraded at Evercore ISI on nex-z hypothesis
Positive Sentiment: Brookline Capital Markets raised its fourth-quarter 2026 EPS forecast to a loss of $0.41 from $0.47, while projecting a path to profitability beginning in 2027. That outlook supports the longer-term investment case, although the firm made broader reductions to its estimates. Brookline Capital Markets estimates
Neutral Sentiment: Bank of America Securities maintained a Hold rating, indicating the firm sees neither a sufficiently strong near-term catalyst nor enough downside to change its stance. Bank of America Securities remains a Hold on Intellia Therapeutics
Negative Sentiment: Intellia’s second-quarter loss was in line with expectations, but revenue fell about 46% year over year to $7.66 million, missing estimates of roughly $12.98 million. The decline was attributed to lower revenue from the Regeneron collaboration, highlighting the company’s reliance on partnership income while it continues to spend heavily on research and development. NTLA Q2 earnings in line, top line misses on lower Regeneron revenues
Negative Sentiment: Brookline lowered its estimates for the second and third quarters of 2026 and reduced its full-year 2026 forecast to a $2.84 per-share loss. More significantly, projected EPS was cut for 2027 through 2030, including a reduction in 2030 estimates from $68.52 to $25.07, signaling lower expectations for the eventual commercial opportunity.
Negative Sentiment: WallStreetZen downgraded NTLA to Strong Sell, adding to the bearish analyst commentary and reinforcing concerns about continued losses, execution risk and valuation. Intellia lowered to Strong Sell rating

About Intellia Therapeutics

(Get Free Report)

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.